GlassScriptPhysician profile
Mona S Walimbe
NPI 1275730871
$1,994.59
in general payments reported to CMS, 2019-2025
33 companies · $743 in 2025
The $743 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $56.86 · 2021: $30.62 · 2022: $141 · 2023: $187 · 2024: $563 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $301.74 | 2019-2025 | Jardiance, Zepbound, Taltz |
| Novo Nordisk INC | $258.35 | 2019-2025 | Wegovy, Ozempic, Sogroya |
| Medtronic, INC. | $162.63 | 2024-2025 | Minimed 780g, Synchromedii |
| Janssen Biotech, INC. | $137.07 | 2022-2025 | Tremfya |
| Dexcom, INC. | $132.71 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $120.82 | 2019 | |
| Amgen INC. | $108.57 | 2020-2025 | Evenity, Uplizna |
| Biogen, INC. | $71.98 | 2024 | Vumerity, Tysabri |
| Vanda Pharmaceuticals INC. | $68.41 | 2024-2025 | Ponvory |
| Ascensia Diabetes Care US INC. | $57.97 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.03 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Recordati_rare_diseases_inc. | $46.94 | 2024-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $46.44 | 2021-2025 | Gvoke Hypopen |
| Abbott Laboratories | $41.61 | 2022-2025 | Freestyle Libre |
| Cequr Corporation | $36.98 | 2022-2023 | Cequr Simplicity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $36.63 | 2019-2023 | Omnipod |
| Abbvie INC. | $31.48 | 2020-2024 | |
| Tandem Diabetes Care, INC. | $28.67 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $27.78 | 2019 | |
| Genzyme Corporation | $21.86 | 2024 | |
| Grifols USA, LLC | $20.20 | 2025 | Gamunex-C |
| Calliditas Therapeutics US INC. | $18.62 | 2025 | Tarpeyo |
| Argenx US, INC. | $18.52 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Ascendis Pharma Endocrinology INC | $17.92 | 2025 | Yorvipath |
| Corcept Therapeutics | $17.09 | 2025 | Korlym |
| Almatica Pharma LLC | $15.91 | 2024 | Teriparatide |
| Amneal Pharmaceuticals LLC | $15.57 | 2024 | Unithroid |
| Mallinckrodt Hospital Products INC. | $15.36 | 2024 | Acthar |
| Pfizer INC. | $14.69 | 2023 | |
| Clarus Therapeutics INC. | $14.25 | 2021 | |
| Amarin Pharma, INC. | $13.64 | 2023 | |
| Medtronic Minimed, INC. | $13.03 | 2019 | |
| Glaxosmithkline, LLC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Walimbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.